CODX Free Cash Flow Yield vs Capex To Depreciation Analysis
CODX Stock | USD 1.01 0.05 4.72% |
Co Diagnostics financial indicator trend analysis is way more than just evaluating Co Diagnostics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Co Diagnostics is a good investment. Please check the relationship between Co Diagnostics Free Cash Flow Yield and its Capex To Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Co Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy CODX Stock please use our How to Invest in Co Diagnostics guide.
Free Cash Flow Yield vs Capex To Depreciation
Free Cash Flow Yield vs Capex To Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Co Diagnostics Free Cash Flow Yield account and Capex To Depreciation. At this time, the significance of the direction appears to have very week relationship.
The correlation between Co Diagnostics' Free Cash Flow Yield and Capex To Depreciation is 0.21. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of Co Diagnostics, assuming nothing else is changed. The correlation between historical values of Co Diagnostics' Free Cash Flow Yield and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Co Diagnostics are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Free Cash Flow Yield i.e., Co Diagnostics' Free Cash Flow Yield and Capex To Depreciation go up and down completely randomly.
Correlation Coefficient | 0.21 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Most indicators from Co Diagnostics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Co Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Co Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy CODX Stock please use our How to Invest in Co Diagnostics guide.Selling General Administrative is likely to rise to about 15 M in 2024, despite the fact that Tax Provision is likely to grow to (9.3 M).
Co Diagnostics fundamental ratios Correlations
Click cells to compare fundamentals
Co Diagnostics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Co Diagnostics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.2M | 71.2M | 160.0M | 123.1M | 95.3M | 50.6M | |
Total Current Liabilities | 328.1K | 4.5M | 12.6M | 3.9M | 5.7M | 3.8M | |
Total Stockholder Equity | 1.7M | 66.7M | 134.5M | 114.5M | 86.0M | 44.2M | |
Net Tangible Assets | 1.7M | 66.7M | 92.6M | 87.8M | 100.9M | 106.0M | |
Retained Earnings | (25.0M) | 17.5M | 54.2M | 39.9M | 4.6M | 5.5M | |
Accounts Payable | 6.0K | 598.3K | 607.5K | 952.3K | 1.5M | 1.6M | |
Cash | 893.1K | 43.0M | 88.6M | 23.0M | 14.9M | 19.4M | |
Cash And Short Term Investments | 893.1K | 47.3M | 89.9M | 81.3M | 58.5M | 31.2M | |
Capital Surpluse | 26.7M | 49.2M | 80.3M | 88.5M | 101.7M | 106.8M | |
Total Liab | 478.1K | 4.5M | 25.6M | 8.6M | 9.3M | 6.4M | |
Total Current Assets | 1.6M | 68.4M | 115.1M | 92.7M | 62.1M | 38.2M | |
Common Stock | 17.3K | 28.6K | 33.8K | 34.8K | 36.1K | 22.9K | |
Property Plant Equipment | 196.8K | 949.6K | 1.9M | 2.5M | 2.9M | 3.1M | |
Other Current Liab | 320.8K | 3.4M | 9.6M | 1.1M | 1.6M | 2.2M | |
Property Plant And Equipment Net | 196.8K | 949.6K | 1.9M | 2.9M | 6.0M | 6.3M | |
Net Debt | (893.1K) | (43.0M) | (88.6M) | (22.6M) | (11.9M) | (12.5M) | |
Non Current Assets Total | 631.1K | 2.9M | 44.9M | 30.4M | 33.2M | 34.8M | |
Non Currrent Assets Other | (631.1K) | 1.4M | (484.9K) | 672.7K | (1.0) | (0.95) | |
Net Receivables | 131.4K | 12.1M | 20.9M | 5.4M | 330.9K | 314.3K | |
Common Stock Total Equity | 17.3K | 28.6K | 33.8K | 34.8K | 40.0K | 21.9K | |
Common Stock Shares Outstanding | 16.8M | 28.0M | 29.9M | 31.5M | 29.3M | 22.2M | |
Liabilities And Stockholders Equity | 2.2M | 71.2M | 160.0M | 123.1M | 95.3M | 56.2M | |
Non Current Liabilities Total | 150K | 30K | 13.0M | 4.7M | 3.6M | 2.8M | |
Other Current Assets | 362.6K | 916.3K | 2.3M | 761.2K | 1.6M | 889.4K | |
Other Stockholder Equity | 26.7M | 49.2M | 80.3M | 74.3M | 81.2M | 42.8M | |
Property Plant And Equipment Gross | 196.8K | 949.6K | 2.6M | 4.3M | 8.2M | 8.6M | |
Other Liab | 150K | 30K | 13.0M | 4.6M | 5.3M | 3.3M | |
Retained Earnings Total Equity | (25.0M) | 17.5M | 54.2M | 39.9M | 45.9M | 48.2M | |
Inventory | 197.2K | 8.0M | 2.0M | 5.3M | 1.7M | 2.7M | |
Net Invested Capital | 1.7M | 66.7M | 134.5M | 114.5M | 86.0M | 64.1M | |
Long Term Investments | 434.2K | 1.9M | 75K | 672.7K | 773.4K | 671.4K | |
Net Working Capital | 1.3M | 63.8M | 102.5M | 88.9M | 56.4M | 49.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.